Search

Fermented dairy products have been produced and consumed for thousands of years in Xinjiang, China. In this study, traditional culture-dependent methods and 16S rRNA gene analyses were performed to...

Traditional fermented dairy foods including cottage cheese have been major components of the Buryatia diet for centuries. Buryatian cheeses have maintained not only their unique taste and flavor but also their rich natural lactic acid bacteria (LAB) content. However, relatively few studies have described their microbial communities or explored their potential to serve as LAB resources. In this study, the bacterial microbiota community of 7 traditional artisan cheeses produced by local Buryatian families was investigated using single-molecule, real-time sequencing. In addition, we compared the bacterial microbiota of the Buryatian cheese samples with data sets of cheeses from Kazakhstan and Italy. Furthermore, we isolated and preserved several LAB samples from Buryatian cheese. A total of 62 LAB strains (belonging to 6 genera and 14 species or subspecies) were isolated from 7 samples of Buryatian cheese. Full-length 16S rRNA sequencing of the microbiota revealed 145 species of 82 bacterial genera, belonging to 7 phyla. The most dominant species was Lactococcus lactis (43.89%). Data sets of cheeses from Italy and Kazakhstan were retrieved from public databases. Principal component analysis and multivariate ANOVA showed marked differences in the structure of the microbiota communities in the cheese data sets from the 3 regions. Linear discriminant analyses of the effect size identified 48 discriminant bacterial clades among the 3 groups, which might have contributed to the observed structural differences. Our results indicate that the bacterial communities of traditional artisan cheeses vary depending on geographic origin. In addition, we isolated novel and valuable LAB resources for the improvement of cottage cheese production.

Instead of using traditional separate phase I and II trials, in this article, we propose using a parallel three-stage phase I/II design, incorporating a dose expansion approach to flexibly evaluate the safety and efficacy of dose levels, and to select the optimal dose. In the proposed design, both the toxicity and efficacy responses are binary endpoints. A 3+3-based procedure is used for initial period of dose escalation at stage 1; at this level, the dose can be expanded to stage 2 for exploratory efficacy studies of phase IIa, while simultaneously, the safety testing can advance to a higher dose level. A beta-binomial model is used to model the efficacy responses. There are two placebo-controlled randomization interim monitoring analyses at stage 2 to select the promising doses to be recommended to stage 3 for further efficacy studies of phase IIb. An adaptive randomization approach is used to assign more patients to doses with higher efficacy levels at stage 3. We examine the properties of the proposed...